Related Experiment Video
Updated: Dec 11, 2025

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
Published on: December 7, 2012
Inappropriate Prescription of Direct Oral Anticoagulant Starter Packs
Yilin Feng1, Chih-Wen Pai2, Kristian Seiler3
1University of Michigan Medical School, Ann Arbor.
Insights
Direct oral anticoagulant starter packs are often inappropriately prescribed for conditions other than venous thromboembolism. This study found 20.7% of starter packs were potentially inappropriate, highlighting risks for older patients.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Health Services Research
Background:
- Direct oral anticoagulants (DOACs) are widely used for venous thromboembolism (VTE).
- DOAC starter packs aim to simplify treatment initiation.
- Concerns exist regarding the appropriateness of DOAC starter pack use in non-VTE indications.
Purpose of the Study:
- To evaluate the rate of inappropriate prescription of DOAC starter packs.
- To identify patient characteristics associated with inappropriate DOAC starter pack prescriptions.
Main Methods:
- Retrospective analysis of national outpatient pharmacy claims data (2015-2018).
- Inclusion of adult patients with continuous insurance coverage.
- Definition of inappropriate prescription as lacking a VTE diagnosis or prior starter pack fill within 45 days.
Main Results:
- 3711 DOAC starter pack fills were analyzed from 3634 unique patients.
- 20.7% (770 fills) were identified as potentially inappropriate.
- Patients with inappropriate fills were significantly older (64.7 vs 62.4 years).
Conclusions:
- A substantial proportion of DOAC starter packs are prescribed without a VTE diagnosis.
- Inappropriate prescribing raises concerns for potential bleeding complications.
- Further research is needed to understand and mitigate inappropriate DOAC starter pack use.
Background:
The 30-day direct oral anticoagulant starter pack has simplified the treatment of acute venous thromboembolisms, but it is not appropriate for use in patients with other indications for anticoagulation.
Methods:
A retrospective analysis of national outpatient pharmacy claims data between January 1, 2015 and December 31, 2018, was performed. Adult patients (ages >18 years) with continuous insurance enrollment at least 12 months prior to and 1 month following a direct oral anticoagulant starter pack prescription during the study period were included. The primary study outcome was the rate of inappropriate prescription of direct oral anticoagulant starter packs, defined as a prescription without a venous thromboembolism diagnosis within the prior 45 days or a prescription with a prior starter pack fill within the past 45 days.
Results:
A total of 3711 direct oral anticoagulant starter pack prescription fills were identified, representing 3634 unique patients. The mean patient age was 62.8 years (standard deviation [SD] 15.1) and 1871 (50.4%) were females. There were 770 (20.7%) direct oral anticoagulant starter pack fills identified as potentially inappropriate. Patients prescribed inappropriate fills were likely to be older than patients with appropriate fills (64.7 years vs 62.4 years, P < 0.001). There was no significant difference in the race or geographic location between patients with inappropriate and appropriate prescriptions.
Conclusions:
A significant proportion of patients using direct oral anticoagulant starter packs did not have a diagnosis of acute venous thromboembolism, raising concerns about inappropriate prescribing and potential bleeding complications. Future studies are needed to identify factors associated with inappropriate direct oral anticoagulant starter pack prescription and evaluate efforts to reduce this practice.
More Related Videos
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...

